Kindstar Globalgene Technology, Subsidiary to Acquire Biotech Medical Companies

MT Newswires Live
2024-09-23

Kindstar Globalgene Technology (HKG:9960) agreed to acquire a 100% stake in the US company AnchorDx from AnchorDx HK.

Kindstar Global Medical Technology (Wuhan), a subsidiary of the company, agreed to acquire a 100% stake in Guangzhou Kangcheng Weiye Biotechnology from its owners, a Friday filing with the Hong Kong Exchange said.

The total consideration for both acquisitions comes in at $31.3 million. The group plans to pay for the acquisition of Guangzhou Kangcheng Weiye Biotechnology in cash through bank borrowings and net proceeds from the global offering.

For the acquisition of AnchorDx US, the company plans to issue 15,869,521 consideration shares to Wuxi Anchor and 43,561,835 shares to OrbiMed at a consideration price of HK$1.42 per share.

As per regulations, the existing contractual arrangements between Guangzhou Kangcheng, Guangzhou Jizhun Medical, and the latter's registered shareholders will be dissolved and new contracts will be entered into by the relevant parties.

The high-end esoteric testing service provider company's shares were up over 2% on Monday's close.

Price (HKD): $1.25, Change: $+0.030, Percent Change: +2.46%

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10